Table 1 Relationship between ratios of BCLAF1 exon5a+/exon5a− in colorectal carcinoma and clinical and pathological features of the individuals.
From: BCLAF1 and its splicing regulator SRSF10 regulate the tumorigenic potential of colon cancer cells
Clinical characteristics | Non-increased BCLAF1 exon5a+/exon5a− ( n =55) No (%) | Increased BCLAF1 exon5a+/exon5a− ( n =45) No (%) | Test of significance |
|---|---|---|---|
Gender | |||
Male | 32 (54.2) | 27 (45.8) | c2=0.0338 |
Female | 23 (56.1) | 18 (43.9) | P=0.8541 |
Age (years) | |||
≤50 | 5 (62.5) | 3 (37.5) | |
>50 | 50 (54.3) | 42 (45.7) | P=0.7269* |
Tumour site | |||
Colon (L) | 16 (48.5) | 17 (51.5) | |
Colon (R) | 15 (57.7) | 11 (42.3) | c2=0.8493 |
Rectum | 24 (58.5) | 17 (41.5) | P=0.6540 |
TNM stage | |||
T1 | 2 (100.0) | 0 (0.0) | |
T2 | 7 (58.3) | 5 (41.7) | |
T3 | 16 (59.3) | 11 (40.7) | |
T4 | 30 (50.8) | 29 (49.2) | P=0.6502* |
N stage | |||
N0 | 31 (59.6) | 21 (40.4) | |
N1 | 11 (42.3) | 15 (57.7) | c2=2.2886 |
N2 | 13 (59.1) | 9 (40.9) | P=0.3184 |
Tumour grade | |||
I | 10 (76.9) | 3 (23.1) | |
II | 21 (60.0) | 14 (40.0) | |
III | 23 (56.1) | 18 (43.9) | |
IV | 1 (9.1) | 10 (90.9) | P=0.0056* |
